{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '18.', 'APPENDICES', 'Appendix A: Table of Abbreviations', 'Table 4:', 'Abbreviations and Specialist Terms', 'Abbreviation or', 'Specialist Term', 'Explanation', 'ADL', 'Activities of daily living', 'AE', 'Adverse event', 'ALT', 'Alanine aminotransferase (SGPT)', 'ANCOVA', 'Analysis of covariance', 'APC', 'Antigen presenting cell', 'APR', 'Apremilast', 'AST', 'Aspartate aminotransferase (SGOT)', 'ATC', 'Anatomical Therapeutic Chemical', '\u00df-hCG', 'Beta human chorionic gonadotropin', 'BID', 'Twice daily', 'BMI', 'Body mass index', 'BSA', 'Body surface area', 'BUN', 'Blood urea nitrogen', 'cAMP', 'Cyclic adenosine monophosphate', 'CBC', 'Complete blood count', 'CI', 'Confidence interval', 'CIN', 'Cervical intraepithelial neoplasia', 'CMH', 'Cochran-Mantel-Haenszel', 'CRO', 'Contract Research Organization', 'CLcr', 'Creatinine clearance', 'CRF', 'Case report form', 'DLQI', 'Dermatology Life Quality Index', 'DMARD', 'Disease-modifying antirheumatic drug', 'EC', 'Ethics Committee', 'eCRF', 'Electronic case report form', 'EEA', 'European Economic Area', 'eGFR', 'Estimated glomerular filtration rate', 'Confidential and Proprietary', '72', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 4:', 'Abbreviations and Specialist Terms (Continued)', 'Abbreviation or', 'Specialist Term', 'Explanation', 'EMA', 'European Medicines Agency', 'EOT', 'End of treatment', 'EQ-5D', 'European Quality of Life 5-Dimension Questionnaire', 'FCBP', 'Females of childbearing potential', 'FDA', 'Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'GEE', 'Generalized estimating equations', 'GGT', 'Gamma-Glutamyl Transferase', 'HDPE', 'High-density polyethylene', 'IB', \"Investigator's Brochure\", 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonisation', 'IL', 'Interleukin', 'IP', 'Investigational product', 'IRB', 'Institutional Review Board', 'IRT', 'Interactive response technology', 'ITT', 'Intent to treat', 'IUD', 'Intrauterine device', 'LDH', 'Lactate Dehydrogenase', 'MCH', 'Mean Corpuscular Hemoglobin', 'MCHC', 'Mean Corpuscular Hemoglobin Concentration', 'MCV', 'Mean Corpuscular Volume', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MG', 'Milligrams', 'MI', 'Multiple imputation', 'MMRM', 'Mixed-Effect Model Repeated Measure', 'Modified sPGA-G', 'Modified Static Physicians Global Assessment of Genitalia', 'NAPSI', 'Nail Psoriasis Severity Index', 'NRS', 'Numeric Rating Scale', 'Confidential and Proprietary', '73', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 4:', 'Abbreviations and Specialist Terms (Continued)', 'Abbreviation or', 'Specialist Term', 'Explanation', 'PASI', 'Psoriasis Area Severity Index', 'PBI', 'Patient Benefit Index', 'PBQ', 'Patient Benefit Questionnaire', 'PDE', 'Phosphodiesterase', 'PDE4', 'Phosphodiesterase type 4', 'PNQ', 'Patient Needs Questionnaire', 'PP', 'Per protocol', 'PPPGA', 'Palmoplantar Psoriasis Physicians Global Assessment', 'PC', 'Product Complaint', 'PUVA', 'Psoralens and long-wave ultraviolet radiation', 'QOL', 'Quality of life', 'RBC', 'Red blood cell', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SC', 'Steering committee', 'ScPGA', 'Scalp Physician Global Assessment', 'SGOT', 'Serum glutamic oxaloacetic transaminase', 'SGPT', 'Serum glutamic pyruvic transaminase', 'SOP', 'Standard operating procedure', 'sPGA', 'static Physicians Global Assessment', 'sPGA-G', 'static Physicians Global Assessment of Genitalia', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'TNF', 'Tumor necrosis factor', 'UVB', 'Ultraviolet light B', 'VAS', 'Visual Analog Scale', 'WBC', 'White blood cell', 'WHO', 'World Health Organization', 'WPAI: PSO', 'Work Productivity and Activity Impairment Questionnaire: Psoriasis', 'Confidential and Proprietary', '74', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}